CAPRICOR THERAPEUTICS, INC. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Capricor submitted a major BLA amendment for Deramiocel (CAP-1002) for DMD, adding two-year HOPE-3 open-label extension data showing 76% slower upper limb decline in patients who switched from placebo to treatment, with a refined indication focused on upper limb impairment in patients 9 years old. The FDA extended review by three months to November 22, 2026. Cash position stands at $198.5M as of September 30, 2026, down from $318.1M at year-end 2025; nine-month 2026 net loss was $117.3M versus $74.9M in 2026, with operating expenses rising 57% year-over-year to $124.4M driven by pre-commercial activities and manufacturing scale-up.
Why this rating
Lead asset approaching regulatory decision with supportive efficacy data; 50% cash burn rate sustainable ~2 years; rare disease approval potential high, but binary outcome imminent.
Tradability signal
SHORT
conviction 19/100 · expected -0.41% over 4 hrs
SHORT (fade the pop): stock already ran +8.0% on this news, and positive calls in this cell have historically given the pop back (-0.43% over 4 hrs, n=441). Reversion play, lower conviction by design. Exit plan: HARD stop 7.4% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $8.90 ▲ 0.34% | at our read · unknown $8.87 | +10 min · unknown $9.60 ▲ 8.23% | +30 min · unknown $9.76 ▲ 10.03% | +1 hr · unknown $10.29 ▲ 16.07% | +4 hrs · unknown $10.58 ▲ 19.28% |
The stock had already moved -0.34% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.